Monoclonal Anti-DM-1 Antibody, Rabbit IgG (M5D04)

Antibody Internalization Detection Reagent (IGG-PZF2001) monitors endocytosis in live cells
製品番号/仕様
価格
Availability
数量
DM1-MY2358-100ug
$315.00
In Stock - Delivery in 2-3 business days
DM1-MY2358-1mg (500ug X 2)
$1,890.00
In Stock - Delivery in 2 weeks
DM1-MY2358
製品金額 :
$ 0
推奨新製品 Request Quote
Contact Us
Contact Us
製品金額:
$ 0
  • 製品詳細
  • データ表示
  • Reviews & Citations
  • Important Statement
  • Resources
Source

Chimeric Monoclonal Anti-DM-1 Antibody, Rabbit IgG (M5D04) is recombinantly expressed in HEK293. It consists of rabbit variable regions genetically fused to rabbit IgG constant domains.

Antibody Type

Recombinant Monoclonal

Clone

M5D04

Isotype

Rabbit IgG, Kappa

Host Species

Rabbit

Immunogen

DM-1-BSA

Specificity

Specifically recognizes the target DM-1 & DM-4.

Application
Application
Recommended Use / Performance
ELISA
0.2-2 μg/mL
Purification

Protein A purified.

Concentration

Please refer to the Certificate of Analysis (CoA).

Form

Lyophilized

Formulation

Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.

Please contact us for customized product forms or formulations.

Reconstitution

Please refer to the Certificate of Analysis (CoA) for specific instructions.

Shipping

Lyophilized product is shipped at ambient temperature.

Storage

For long term storage, the product should be stored in a lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 12 months in lyophilized state;
  • -70°C for 3 months under sterile conditions after reconstitution.
Notices

Product Specific Notices: For research use only.

バックグランド

DM1, a maytansinoid derivative, is a common payload toxin in antibody-drug conjugates (ADCs). It binds to tubulin, hinders microtubule assembly, arrests cell division, and induces apoptosis, but has off-target toxicity. ADCs like T-DM1 have shown good efficacy in HER2-positive cancers. For recent progress, many new DM1-containing ADCs are under development. For example, GQ1001 has entered Phase I clinical trials for HER2+ advanced solid tumors, and some have demonstrated antitumor activity in T-DM1-resistant models in preclinical studies.